

The effect of Kineret® on brain biomarkers in patients with subarachnoid haemorrhage

| | | |
|--|---|---|
| Submission date 06/11/2008 | Recruitment status No longer recruiting | <input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 18/12/2008 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 21/04/2020 | Condition category Circulatory System | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

A spontaneous subarachnoid haemorrhage (SAH) is a serious medical condition caused by sudden bleeding over the surface of the brain. It is most often caused when a bulge in a blood vessel wall (brain aneurysm) bursts (ruptures) because the vessel wall has become weakened over time. Following rupture blood pools inside the skull (which cannot expand due to its rigid structure) leading to pressure on the brain and starving it of oxygen (cerebral ischaemia) causing further brain damage. To treat this, a hole is usually drilled into the skull and a tube (external ventricular drain) is placed inside so that the collected blood can escape, lowering pressure on the brain. When a person sustains a severe injury chemicals are released in the body to help start the healing process, such as the protein Interleukin-1 (IL-1) which triggers inflammation (swelling). Studies have shown that IL-1 actually contributes to the damage caused cerebral ischaemia. Kineret® is a drug which acts by blocking the action of IL-1. The aim of this study is to find out whether Kineret® can change the concentration of the inflammatory biomarkers (natural chemical indicators of inflammation) in the blood and cerebral spinal fluid (fluid that cushions the brain).

Who can participate?

Patients aged 16 years or over who have had a spontaneous subarachnoid haemorrhage (SAH) and have had an external ventricular drain (EVD) fitted.

What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group are a bolus (one-off large dose) injection of 500mg Kineret® into a vein (IV) over 1 minute. Immediately afterwards, the participants are started on a drip (infusion) of Kineret® which is given slowly, over 24 hours. Those in the second group are given a bolus injection of a placebo (dummy) over one minute, followed by an infusion of saline (salt water) and placebo (dummy) over 24 hours. Participants in both groups have samples of blood and cerebral spinal fluid (CSF) taken at the start of the study and then after 6, 12, 24, 36, 48 and 72 hours in order to measure the concentration of the chemical indicators of inflammation (inflammatory biomarkers).

What are the possible benefits and risks of participating?

Not provided at time of registration

Where is the study run from?

Brain Injury Research Group, Salford Royal NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

June 2009 to April 2010

Who is funding the study?

Medical Research Council (UK)

Who is the main contact?

Dr Pippa Tyrrell

pippa.tyrrell@manchester.ac.uk

Study website

<http://www.hope-academic.org.uk/misah/Study2.html>

Contact information

Type(s)

Scientific

Contact name

Dr Pippa Tyrrell

ORCID ID

<http://orcid.org/0000-0001-9609-1231>

Contact details

Brain Injury Research Group

Clinical Sciences Building

Salford Royal Foundation Trust

Stott Lane

Salford

United Kingdom

M6 8HD

+44 (0)161 206 2018

pippa.tyrrell@manchester.ac.uk

Additional identifiers

EudraCT/CTIS number

2007-005836-98

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

MRC ref: G0502030; Protocol version 2 16-07-2008

Study information

Scientific Title

The effect of Kineret® on brain biomarkers in patients with subarachnoid haemorrhage: Double-blind randomised placebo-controlled trial

Study objectives

The presence of Kineret® in the cerebrospinal fluid (CSF) at concentrations that have been shown to be experimentally therapeutic decrease concentrations of inflammatory biomarkers in the CNS.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added 05/06/2009: Wales REC approved on the 29th January 2009 (ref: 09/MRE09/1)

Study design

Single-centre double-blind randomised placebo-controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Subarachnoid haemorrhage

Interventions

The study is a double-blind randomised controlled trial of Kineret® with participants with an external ventricular drain (EVD) inserted as part of their clinical care. Participants will be randomised to receive a regime of 500 mg bolus dose plus a 10 mg/kg/h intravenous infusion for 24 hours of Kineret® or placebo, which has been identified from a previous pharmacokinetic dose-finding study. Blood and CSF will be taken immediately prior to bolus dose of IMP/placebo (baseline); and at 6, 12 and 24 hours (during period of infusion) and then at 36, 48 and 72 hours (from time of bolus injection). A final sample will be obtained at Day 7 (study end) if the participant still has an EVD in-situ. Analysis of these samples will show the effect of Kineret® on inflammatory markers and allow the concentration of the markers to be measured.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Interleukin-1 (IL-1), (Kineret®)

Primary outcome measure

To determine whether intravenously administered Kineret® causes a decrease in the concentration of central inflammatory biomarkers in the blood and CSF samples following SAH compared to placebo. The following markers will be assessed: C-reactive protein (CRP), IL-1RA, IL-1a, IL-1β, IL-6, IL-8, IL-10

Blood and CSF samples will be taken immediately prior to bolus dose of IMP/placebo (baseline); and at 6, 12 and 24 hours (during period of infusion) and then at 36, 48 and 72 hours (from time of bolus injection). A final sample will be obtained at Day 7 (study end) if the participant still has an EVD in-situ.

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/06/2009

Completion date

30/04/2010

Eligibility**Key inclusion criteria**

1. Both males and females, aged 16 years or above
2. Patients with confirmed spontaneous subarachnoid haemorrhage (SAH) who have had an external ventricular drain (EVD) inserted as part of their clinical care
3. No concomitant health problems that, in the opinion of the Principal Investigator or Chief Investigator or designee, would interfere with participation, administration of study treatment or assessment of outcomes including safety, for example, pre-existing malignancy
4. No confirmed or suspected serious infection at the time of study entry
5. Renal function within normal limits (serum creatinine <177 µmol/l)
6. Willing and able to give informed consent or consent available from a patient representative (personal, usually the next of kin) for study inclusion including agreement in principle to receive study intervention and undergo all study assessments

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

32

Total final enrolment

18

Key exclusion criteria

1. Known or suspected infection at the time of consideration for the study
2. Known allergy to E. coli or any of the constituents of the study medication as established from the patient themselves, reliable representative and clinical records
3. Previous or concurrent treatment with anakinra or Kineret®; known at the time of study entry
4. Previous or current treatment with medication suspected of interacting with Kineret®, such as TNF- α inhibitors
5. Evidence of serious infection
6. Known to have participated in a clinical trial of an investigational agent or device in the previous 30 days or for the period determined by the protocol of the study the patient has taken part in
7. Known pregnancy or breast-feeding
8. Clinically significant concurrent medical condition, which in the Chief Investigator's (or designee's) discretion, could affect the safety, tolerability, or efficacy in this study
9. Previous inclusion in current study (known prior to inclusion)
10. Inability or unwillingness of patient or patient's personal representative to give written informed consent

Date of first enrolment

01/06/2009

Date of final enrolment

30/04/2010

Locations**Countries of recruitment**

England

United Kingdom

Study participating centre

Brain Injury Research Group

Salford Royal NHS Foundation Trust

Salford

United Kingdom

M6 8HD

Sponsor information

Organisation

Salford Royal Hospitals NHS Trust (UK)

Sponsor details

Research and Development Directorate

Clinical Sciences Building

Stott Lane

Salford

England

United Kingdom

M6 8HD

+44 (0)161 206 7373/5755

lloyd.gregory@manchester.ac.uk

Sponsor type

Hospital/treatment centre

Website

<http://www.hope-academic.org.uk/Academic/researchdevelopment/>

ROR

<https://ror.org/019j78370>

Funder(s)

Funder type

Government

Funder Name

Medical Research Council (UK) (Grant ref: G0502030)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration.

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|--------------------------------------|---------|--------------|------------|----------------|-----------------|
| Basic results | results | 01/02/2016 | 21/04/2020 | No | No |
| Results article | | | 21/04/2020 | Yes | No |
| HRA research summary | | | 28/06/2023 | No | No |